Personalized multichannel transcranial direct current electrical stimulation (tDCS) in drug-resistant epilepsy: A SEEG based open-labeled study.

IF 2.8 3区 医学 Q2 CLINICAL NEUROLOGY
Epilepsia Open Pub Date : 2025-05-10 DOI:10.1002/epi4.70055
Fabrice Bartolomei, Maëva Daoud, Megane Delourme, Sophie Tardoski, Julia Makhalova, Eya Bourguiba, Samuel Medina Villalon, Stanislas Lagarde, Fabrice Wendling, Giulio Ruffini, Ricardo Salvador, Francesca Pizzo, Bernard Giusiano
{"title":"Personalized multichannel transcranial direct current electrical stimulation (tDCS) in drug-resistant epilepsy: A SEEG based open-labeled study.","authors":"Fabrice Bartolomei, Maëva Daoud, Megane Delourme, Sophie Tardoski, Julia Makhalova, Eya Bourguiba, Samuel Medina Villalon, Stanislas Lagarde, Fabrice Wendling, Giulio Ruffini, Ricardo Salvador, Francesca Pizzo, Bernard Giusiano","doi":"10.1002/epi4.70055","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of personalized multichannel tDCS on seizure frequency, severity, quality of life, and psychiatric comorbidities in patients with drug-resistant focal epilepsy. Secondary goals include assessing the safety and feasibility of this approach.</p><p><strong>Methods: </strong>This open-label pilot study involved 16 patients with drug-resistant focal epilepsy. Patients underwent 3 cycles of personalized multichannel tDCS over 6 months, targeting the EZ defined by stereoelectroencephalography (SEEG). Each cycle consisted of five consecutive days of tDCS, with two daily sessions of 20 min each. The primary endpoint was a reduction in seizure frequency, with secondary endpoints addressing quality of life (QOLIE-31 scores), seizure severity (NHS3 scores), and psychiatric comorbidities (NDDI-E and GAD-7 scales).</p><p><strong>Results: </strong>Across all participants, a statistically significant 20% reduction in seizure frequency was observed (p = 0.044). Six patients (37%) were identified as responders (≥50% seizure reduction), with one achieving seizure freedom. The mean seizure reduction among responders was 68%. Significant improvements were noted in overall quality of life (QOLIE-31, p = 0.009), with greater benefits for patients with poorer baseline scores. No overall significant changes were observed in depression, anxiety, and seizure severity scores, though individual variability was noted. The treatment was well tolerated, with mild adverse events, primarily skin-related.</p><p><strong>Significance: </strong>Personalized multichannel tDCS shows promise as a noninvasive therapeutic option for drug-resistant focal epilepsy, with benefits in seizure reduction and quality of life. Although results were variable, the method's safety and feasibility support further exploration through randomized controlled trials to refine protocols, better select potential responders' patients, and validate findings.</p><p><strong>Plain language summary: </strong>This study tested a personalized brain stimulation technique called tDCS in people with difficult-to-treat epilepsy. The treatment led to fewer seizures in some patients and improved their quality of life. The approach was safe and caused only mild side effects. These results suggest that this type of noninvasive brain stimulation may be a helpful new option for people who do not benefit from medication or surgery.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/epi4.70055","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the effects of personalized multichannel tDCS on seizure frequency, severity, quality of life, and psychiatric comorbidities in patients with drug-resistant focal epilepsy. Secondary goals include assessing the safety and feasibility of this approach.

Methods: This open-label pilot study involved 16 patients with drug-resistant focal epilepsy. Patients underwent 3 cycles of personalized multichannel tDCS over 6 months, targeting the EZ defined by stereoelectroencephalography (SEEG). Each cycle consisted of five consecutive days of tDCS, with two daily sessions of 20 min each. The primary endpoint was a reduction in seizure frequency, with secondary endpoints addressing quality of life (QOLIE-31 scores), seizure severity (NHS3 scores), and psychiatric comorbidities (NDDI-E and GAD-7 scales).

Results: Across all participants, a statistically significant 20% reduction in seizure frequency was observed (p = 0.044). Six patients (37%) were identified as responders (≥50% seizure reduction), with one achieving seizure freedom. The mean seizure reduction among responders was 68%. Significant improvements were noted in overall quality of life (QOLIE-31, p = 0.009), with greater benefits for patients with poorer baseline scores. No overall significant changes were observed in depression, anxiety, and seizure severity scores, though individual variability was noted. The treatment was well tolerated, with mild adverse events, primarily skin-related.

Significance: Personalized multichannel tDCS shows promise as a noninvasive therapeutic option for drug-resistant focal epilepsy, with benefits in seizure reduction and quality of life. Although results were variable, the method's safety and feasibility support further exploration through randomized controlled trials to refine protocols, better select potential responders' patients, and validate findings.

Plain language summary: This study tested a personalized brain stimulation technique called tDCS in people with difficult-to-treat epilepsy. The treatment led to fewer seizures in some patients and improved their quality of life. The approach was safe and caused only mild side effects. These results suggest that this type of noninvasive brain stimulation may be a helpful new option for people who do not benefit from medication or surgery.

个性化多通道经颅直流电刺激(tDCS)治疗耐药癫痫:一项基于SEEG的开放标签研究
目的:评价个体化多通道tDCS对耐药局灶性癫痫患者发作频率、严重程度、生活质量及精神合并症的影响。次要目标包括评估这种方法的安全性和可行性。方法:这项开放标签的试点研究纳入了16例耐药局灶性癫痫患者。患者在6个月内接受了3个周期的个性化多通道tDCS,目标是立体脑电图(SEEG)定义的EZ。每个周期包括连续五天的tDCS,每天两次,每次20分钟。主要终点是癫痫发作频率的减少,次要终点是生活质量(QOLIE-31评分)、癫痫发作严重程度(NHS3评分)和精神合并症(NDDI-E和GAD-7评分)。结果:在所有参与者中,癫痫发作频率显著降低20% (p = 0.044)。6名患者(37%)被确定为应答者(癫痫发作减少≥50%),其中1名患者实现了癫痫发作自由。应答者的平均癫痫发作减少率为68%。总体生活质量显著改善(QOLIE-31, p = 0.009),基线评分较低的患者获益更大。在抑郁、焦虑和癫痫严重程度评分方面没有观察到总体上的显著变化,尽管注意到个体差异。治疗耐受性良好,不良反应轻微,主要与皮肤有关。意义:个性化多通道tDCS有望成为耐药局灶性癫痫的一种无创治疗选择,在减少癫痫发作和提高生活质量方面有好处。虽然结果是可变的,但该方法的安全性和可行性支持通过随机对照试验进一步探索,以完善方案,更好地选择潜在应答患者,并验证研究结果。简单的语言总结:这项研究在难治性癫痫患者身上测试了一种名为tDCS的个性化脑刺激技术。这种治疗方法减少了一些患者的癫痫发作,提高了他们的生活质量。这种方法是安全的,只产生轻微的副作用。这些结果表明,这种非侵入性脑刺激可能是无法从药物或手术中获益的人的一种有益的新选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epilepsia Open
Epilepsia Open Medicine-Neurology (clinical)
CiteScore
4.40
自引率
6.70%
发文量
104
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信